Small study tests HIV drug dosing in pregnant women
NCT ID NCT04900974
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how pregnancy changes the levels of the HIV drug doravirine in the blood. Seven pregnant women living with HIV took a single dose of doravirine during their second and third trimesters, and again after giving birth. The goal was to find the right dose for pregnant women to keep the drug effective and safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can antimalarials be safely used in early pregnancy? a massive registry seeks answers
- Texts and local mentors: a new way to empower teen girls on contraception?
- Mindfulness during pregnancy: a new way to boost mental health and baby bonding?
- Teaching Moms-to-Be about seafood safety: a new weapon against toxic exposures?
- Can we improve emergency C-Sections for the sickest mothers?